LM-108 plus toripalimab for MSI-H advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two drugs (LM-108 and toripalimab) for people with advanced solid tumors that have a specific marker called MSI-H or dMMR. It is for those whose cancer has grown after previous immunotherapy treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid tumor cancer that cannot be removed with surgery and has a specific marker called MSI-H or dMMR confirmed by the study's lab.
- You are 18 years or older.
- You are able to do daily activities with little to no help (ECOG 0-1).
- You have at least one tumor that can be measured on scans.
- You have already been treated with an anti-PD-1 or anti-PD-L1 immunotherapy drug and the cancer got worse.
- You are willing to provide a stored or new tumor tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.